Friday, November 13, 2026

AUD/USD Went Down By Over 2% In The Last 21 Sessions

Automated market report from our archive (2020–2024), published before source-traceability. How we work

AUD/USD Went Down By Over 2% In The Last 21 Sessions

(VIANEWS) - AUD/USD (AUDUSD) has been up by 2.4% for the last 21 sessions. At 22:07 EST on Tuesday, 30 April, AUD/USD (AUDUSD) is $0.65.

AUD/USD's yearly highs and lows, it's 3.189% up from its 52-week low and 8.742% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AUD/USD's Forex is considered to be overbought (>=80).

Previous days news about AUD/USD (AUDUSD)

  • Aud/usd price analysis: uptrend extends. According to FXStreet on Monday, 29 April, "A decisive break would be one in which AUD/USD formed a long red bearish candlestick on the 4-hr chart that pierced below the channel line and closed near its low, or three consecutive red candles in a row that also broke below the channel line."
  • Aud/usd holds steadily as traders anticipate Australian retail sales, fed’s decision. According to FXStreet on Monday, 29 April, "The AUD/USD is neutrally biased, but it could shift to neutral upwards if buyers reclaim the 100-DMA at 0.6584, followed by the latest cycle high seen at 0.6644, the April 9 high. ", "If the number comes as expected, the AUD/USD could drag lower, but after breaching the 200-day moving average (DMA) of 0.6524, that could be seen as the first support. "

More news about AUD/USD (AUDUSD).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com